8-K: Mirion Technologies Reports Q2 2026 Financial Results

Mirion Technologies announced its second quarter 2026 financial results, showing a 19.7% increase in revenue to $266.8 million, alongside a 27.5% rise in Adjusted EBITDA to $65.3 million.

Summary

• Mirion Technologies reported second quarter 2026 revenues of $266.8 million, a 19.7% increase from $222.9 million in the same period of 2025.
• GAAP net income for the quarter was $8.1 million, a slight decrease from $8.5 million in Q2 2025.
• Adjusted EBITDA saw a significant increase of 27.5%, reaching $65.3 million compared to $51.2 million in the prior year's second quarter.
• GAAP net earnings per share were $0.03, down from $0.04 in Q2 2025, while Adjusted EPS rose to $0.12 from $0.11.
• Second quarter orders, excluding acquisitions, grew 10% to $229 million, and including acquisitions, orders increased 40% to $291 million.
• The company reaffirmed its full-year 2026 guidance for revenue growth, Organic Revenue growth, Adjusted EBITDA, Adjusted Free Cash Flow, and Adjusted EPS.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with strong revenue and Adjusted EBITDA growth, and reaffirmed guidance, despite a slight dip in GAAP net income and EPS. The strategic acquisitions are showing positive results.

Positives

• Revenue increased by 19.7% to $266.8 million in Q2 2026 compared to $222.9 million in Q2 2025.
• Adjusted EBITDA grew by 27.5% to $65.3 million in Q2 2026 from $51.2 million in Q2 2025.
• Adjusted EPS increased to $0.12 in Q2 2026 from $0.11 in Q2 2025.
• Second quarter orders, excluding acquisitions, increased by 10% to $229 million.
• Including acquisitions, second quarter orders surged by 40% to $291 million.
• The company reaffirmed its full-year 2026 financial guidance across key metrics.
• Margin expansion was noted across both operating segments.
• Increased adjusted free cash flow was reported.

Negatives

• GAAP net income decreased by 4.7% to $8.1 million in Q2 2026 from $8.5 million in Q2 2025.
• GAAP net earnings per share decreased to $0.03 in Q2 2026 from $0.04 in Q2 2025.
• Stockholders equity decreased from $1,916.9 million at December 31, 2025, to $1,875.4 million at June 30, 2026.
• Total assets decreased from $3,588.1 million at December 31, 2025, to $3,521.0 million at June 30, 2026.

Risks

• Significant number of factors could cause actual results to differ materially from forward-looking statements, including changes in domestic and foreign business, market, economic, financial, political, and legal conditions.
• Risks related to geopolitical instability, tariffs, sanctions, export controls, trade restrictions, and supply chain disruptions.
• Potential for slowing economic growth or recession in the United States and globally.
• Developments in government budgets, including reductions, sequestration, spending limits, or changes in budgetary priorities.
• Risks related to public perception of nuclear radiation and nuclear technologies.
• Uncertainty in customer capital spending, procurement timing, and project schedules.
• Risks associated with information technology system failures, cybersecurity threats, and data security.
• Potential for product liability claims and the outcome of litigation, government and regulatory proceedings.

Future Outlook

The company reaffirmed its full-year 2026 guidance, expecting total revenue growth of approximately 22.0%-24.0%, Organic Revenue growth of 5.0%-7.0%, Adjusted EBITDA between $285 million and $300 million (with an Adjusted EBITDA margin of 25.0%-26.0%), Adjusted Free Cash Flow of $155 million to $175 million (with a conversion rate of 54%-58% of Adjusted EBITDA), and Adjusted EPS between $0.48 and $0.55 per share. Management anticipates accelerated revenue growth, adjusted free cash flow, and margin expansion in the second half of 2026.

Management Comments

• "Our second quarter performance reflects margin expansion across both operating segments, increased adjusted free cash flow, and continued orders and backlog growth."
• "We captured several large opportunity orders in the second quarter with substantial opportunity available for the rest of the year."
• "Our acquisitions of Certrec and Paragon have augmented our ability to capitalize on growing nuclear power opportunities in North America. Moreover, our global presence puts us at the forefront of international nuclear growth ambitions."
• "We remain well-positioned for second half 2026 accelerated revenue growth, adjusted free cash flow, and margin expansion."
• "We are maintaining our full year 2026 guidance while adjusting the end-market composition of our Medical segment."

Industry Context

StockSavvy.ai notes that Mirion's results align with a growing global demand for nuclear power and advanced radiation detection technologies, driven by energy security concerns and the expansion of nuclear medicine and research. The company's strategic acquisitions appear to be effectively integrating and contributing to growth in key North American markets.

Comparison to Industry Standards

• The revenue growth of 19.7% for Q2 2026 is strong, particularly within the specialized radiation detection and monitoring sector. Competitors like Thermo Fisher Scientific (in its relevant segments) and Smiths Group (in detection technologies) often report growth rates that can vary significantly based on market cycles and specific product demand, but Mirion's performance appears robust.
• The Adjusted EBITDA margin of approximately 24.5% for Q2 2026 (and projected 25.0%-26.0% for the full year) is competitive. Companies in similar industrial technology sectors often aim for EBITDA margins in the high teens to mid-twenties, depending on their business model and scale. For instance, companies focused on highly specialized scientific instrumentation may achieve higher margins than those with broader industrial offerings.

Stakeholder Impact

• Shareholders: Positive impact from revenue growth, increased Adjusted EBITDA, and reaffirmed guidance, suggesting continued value creation. Potential concern over slight decrease in GAAP EPS.
• Employees: Continued growth and successful integration of acquisitions may lead to job security and potential expansion opportunities.
• Customers: Continued investment in solutions for nuclear, medical, defense, and research markets indicates ongoing commitment to serving these sectors.
• Suppliers: Increased order volume suggests sustained demand for components and services, potentially benefiting suppliers.

Next Steps

• Continue to monitor the integration and performance of Certrec and Paragon acquisitions.
• Focus on capitalizing on growing nuclear power opportunities in North America and globally.
• Execute on the reaffirmed full-year 2026 guidance for revenue, Adjusted EBITDA, Adjusted Free Cash Flow, and Adjusted EPS.
• Prepare for the upcoming conference call on July 29, 2026, to discuss results in detail.

Key Dates

Recommendation

The company is performing well with strong revenue and EBITDA growth, and has reaffirmed guidance. However, the slight decrease in GAAP net income and EPS, coupled with the broad list of forward-looking risks, warrants a cautious 'hold' recommendation until further clarity on the macroeconomic environment and the full impact of acquisitions is observed.

Keywords

Radiation detection, Measurement solutions, Monitoring solutions, Nuclear power, Medical technology, Defense industry, Research markets, Financial results